Related Experiment Video
Updated: Apr 3, 2026

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
Published on: August 20, 2019
Loss-of-function mutations of STXBP1 in patients with epileptic encephalopathy
Toshiyuki Yamamoto1, Keiko Shimojima1, Tamami Yano2
1Tokyo Women's Medical University Institute for Integrated Medical Sciences, Tokyo, Japan.
Insights
Syntaxin-binding protein 1 gene (STXBP1) mutations cause early infantile epileptic encephalopathy. This study found four novel STXBP1 mutations, all leading to loss-of-function, suggesting it
Area of Science:
- Genetics and Neurology
- Neurodevelopmental Disorders
Background:
- Epileptic encephalopathy is a severe infantile-onset epilepsy characterized by age-dependent seizures and profound developmental delay.
- Mutations in the syntaxin-binding protein 1 gene (STXBP1) are a known cause of epileptic encephalopathy.
Purpose of the Study:
- To investigate the role of STXBP1 mutations in a cohort of patients with early infantile epileptic encephalopathy.
- To identify novel mutations in STXBP1 and elucidate their functional consequences.
Main Methods:
- A cohort study was conducted involving 42 patients diagnosed with epileptic encephalopathy.
- Genetic analysis was performed to identify mutations in the STXBP1 gene.
- In silico prediction tools were used to assess the functional impact of identified mutations.
Main Results:
- Four novel STXBP1 mutations were identified: two splicing mutations, one frameshift mutation, and one nonsense mutation.
- All identified mutations were predicted to result in a loss-of-function of the STXBP1 protein.
- Patients with STXBP1 mutations exhibited typical epileptic features but showed variable radiological findings, including reduced brain volume and delayed myelination.
Conclusions:
- Loss-of-function is a prevalent mechanism underlying STXBP1-related epileptic encephalopathy.
- STXBP1 mutations are a significant genetic cause of early infantile epileptic encephalopathy.
- While epileptic features are consistent, radiological manifestations in STXBP1-related disorders can be diverse.
Abstract:
Epileptic encephalopathy, which commences during early infancy, is a severe epileptic syndrome that manifests as age-dependent seizures and severe developmental delay. The syntaxin-binding protein 1 gene (STXBP1) is one of the genes responsible for epileptic encephalopathy. We conducted a cohort study to analyze STXBP1 in 42 patients with epileptic encephalopathy. We identified four novel mutations: two splicing mutations, a frameshift mutation, and a nonsense mutation. All of these mutations were predicted to cause loss-of-function. This result suggests loss-of-function is a common mechanism underlying STXBP1-related epileptic encephalopathy. The four patients showed epileptic features consistent with STXBP1-related epileptic encephalopathy, but showed variable radiological findings, including brain volume loss and myelination delay.
More Related Videos
09:37Navigating MARRVEL, a Web-Based Tool that Integrates Human Genomics and Model Organism Genetics Information
Published on: August 15, 2019
08:04Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
Related Concept Videos
Pleiotropy
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...